Biotech and drug stocks
7.48k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop speciality drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three-month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called ‘Battling Cancer’.
Background
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the global financial markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.
How are these weighted?The stocks in this watchlist are weighted equally.
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| Biotech and drug stocks | -0.38% | - | - | - |
| ^GSPC | +0.23% | +3.56% | +24.27% | +5742.73% |
31 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 883.33 | +16.03 | +1.85% | 16:00 GMT-4 | 2.23M | 2.62M | 839.52B |
| NVO | Novo Nordisk A/S | 142.49 | -0.77 | -0.54% | 16:00 GMT-4 | 2.85M | 3.80M | 636.08B |
| JNJ | Johnson & Johnson | 145.45 | +0.04 | +0.03% | 16:00 GMT-4 | 6.72M | 7.66M | 350.05B |
| MRK | Merck & Co., Inc. | 129.37 | -0.83 | -0.64% | 16:00 GMT-4 | 4.78M | 8.15M | 327.67B |
| ABBV | AbbVie Inc. | 166.56 | +0.47 | +0.28% | 16:00 GMT-4 | 3.68M | 5.58M | 294.12B |
| AZN | AstraZeneca PLC | 79.53 | -0.54 | -0.67% | 16:00 GMT-4 | 2.75M | 5.09M | 246.58B |
| RHHBY | Roche Holding AG | 34.53 | +0.50 | +1.47% | 15:59 GMT-4 | 517.27k | 3.14M | 222.27B |
| NVS | Novartis AG | 106.02 | +0.47 | +0.45% | 16:00 GMT-4 | 1.03M | 1.52M | 216.32B |
| AMGN | Amgen Inc. | 298.5 | -2.58 | -0.86% | 16:00 GMT-4 | 1.71M | 2.59M | 160.13B |
| PFE | Pfizer Inc. | 27.65 | -0.01 | -0.04% | 16:02 GMT-4 | 33.80M | 38.83M | 156.68B |
| VRTX | Vertex Pharmaceuticals Incorporated | 479.03 | +3.24 | +0.68% | 16:00 GMT-4 | 807.58k | 1.09M | 123.62B |
| SNY | Sanofi | 47.53 | -0.91 | -1.88% | 16:00 GMT-4 | 2.17M | 2.14M | 119.98B |
| REGN | Regeneron Pharmaceuticals, Inc. | 1026.55 | -1.12 | -0.11% | 16:00 GMT-4 | 295.80k | 437.97k | 113.11B |
| BMY | Bristol-Myers Squibb Company | 41.48 | -0.93 | -2.19% | 16:00 GMT-4 | 15.32M | 15.41M | 84.08B |
| GSK | GlaxoSmithKline plc | 41.11 | - | - | 16:00 GMT-4 | 1.77M | 3.41M | 83.82B |
| GILD | Gilead Sciences, Inc. | 63.56 | -0.78 | -1.21% | 16:00 GMT-4 | 5.74M | 6.98M | 79.19B |
| ZTS | Zoetis Inc. | 171.32 | -4.53 | -2.58% | 16:00 GMT-4 | 2.30M | 3.31M | 78.17B |
| DSNKY | Daiichi Sankyo Company, Limited | 35.52 | -0.42 | -1.17% | 15:09 GMT-4 | 1.15k | 206.19k | 68.35B |
| MRNA | Moderna, Inc. | 145.23 | -2.49 | -1.69% | 16:00 GMT-4 | 1.81M | 3.90M | 55.66B |
| TAK | Takeda Pharmaceutical Company Limited | 13.08 | -0.26 | -1.95% | 16:00 GMT-4 | 1.08M | 1.57M | 41.40B |
| HLN | Haleon plc | 8.48 | +0.16 | +1.92% | 16:00 GMT-4 | 6.25M | 6.76M | 38.72B |
| BIIB | Biogen Inc. | 233.84 | +3.21 | +1.39% | 16:00 GMT-4 | 986.11k | 1.18M | 34.05B |
| BAYRY | Bayer Aktiengesellschaft | 7.35 | -0.17 | -2.26% | 15:52 GMT-4 | 63.78k | 1.99M | 28.96B |
| BNTX | BioNTech SE | 96 | -1.91 | -1.95% | 16:00 GMT-4 | 375.79k | 733.37k | 23.14B |
| ARGX | argenx SE | 388.34 | +5.84 | +1.53% | 16:00 GMT-4 | 166.67k | 264.36k | 23.08B |
| ALNY | Alnylam Pharmaceuticals, Inc. | 160.05 | +1.01 | +0.64% | 16:00 GMT-4 | 390.66k | 549.35k | 20.25B |
| TEVA | Teva Pharmaceutical Industries Limited | 17.4 | +0.18 | +1.05% | 16:00 GMT-4 | 6.51M | 9.64M | 19.71B |
| ALPMY | Astellas Pharma Inc. | 9.59 | -0.20 | -2.04% | 15:55 GMT-4 | 75.69k | 369.62k | 17.23B |
| GMAB | Genmab A/S | 26.41 | -0.36 | -1.34% | 16:00 GMT-4 | 480.76k | 456.11k | 16.98B |
| RPRX | Royalty Pharma plc | 27.2 | - | - | 16:00 GMT-4 | 1.48M | 2.67M | 16.25B |
Yahoo FinanceAstraZeneca CFO: 'We've come a long way in our oncology portfolio'
AstraZeneca is beginning to see momentum behind its oncology portfolio. CFO Aradhana Sarin says the work is only just beginning.
Business WireVertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
BOSTON, June 14, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the annual European Hematology Association (EHA) Congress, confirm the transformative, consistent and durable clinical benefits of CASGEVY over time. CASGEVY is the first and only approved CRI
Business WireNew Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
SANTA MONICA, Calif., June 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced results from three new analyses for Yescarta® (axicabtagene ciloleucel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta, and outpatient administration of both Yescarta and Tecartus® (brexucabtagene autoleucel) at the 2024 European Hematology Association (EHA) Annual Co
